0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%
Last update at 2024-12-19T18:53:00Z
LexisNexis fends off appeal in patent case over lawyer billing software
Tue 12 Nov 24, 05:35 PMPenumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke
Mon 14 Oct 24, 01:00 PMHere's Why You Should Retain Penumbra Stock in Your Portfolio Now
Wed 09 Oct 24, 12:43 PMPEN Stock to Gain From CE Mark Approval for its CAVT Technologies
Tue 17 Sep 24, 12:15 PMUS Exchange: American Healthcare REIT And 2 More Stocks Estimated Below Intrinsic Value
Mon 09 Sep 24, 11:07 AMInsider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ...
Fri 06 Sep 24, 05:49 AMInsider Sale: Director Harpreet Grewal Sells Shares of Penumbra Inc (PEN)
Fri 06 Sep 24, 05:49 AMWhy Is Penumbra (PEN) Up 20% Since Last Earnings Report?
Thu 29 Aug 24, 03:31 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 3.89M | -10.50200M | -38.01800M | 50.13M | 1.61M |
| Minority interest | 0.00000M | 2.66M | -3.55500M | -0.27900M | 0.17M |
| Net income | -2.00200M | 2.62M | -19.25700M | 48.46M | 6.60M |
| Selling general administrative | 449.72M | 378.33M | 287.07M | 272.73M | 226.38M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 535.21M | 475.38M | 338.18M | 371.96M | 292.53M |
| Reconciled depreciation | 24.32M | 16.41M | 12.89M | 8.10M | 6.17M |
| Ebit | -18.23900M | -23.90900M | -51.83300M | 39.40M | 54.65M |
| Ebitda | 6.08M | -7.50100M | -38.94200M | 47.51M | 60.82M |
| Depreciation and amortization | 24.32M | 16.41M | 12.89M | 8.10M | 6.17M |
| Non operating income net other | -2.32700M | -3.93900M | -0.34300M | -0.22700M | -3.60500M |
| Operating income | -18.23900M | -7.50100M | -38.94200M | 47.51M | -0.85200M |
| Other operating expenses | 841.05M | 755.09M | 599.35M | 499.90M | 414.95M |
| Interest expense | 0.14M | 16.07M | 17.37M | 12.19M | 0.00000M |
| Tax provision | 5.89M | -13.12500M | -18.76100M | 3.13M | -4.47800M |
| Interest income | 0.14M | 0.94M | 1.27M | 2.85M | 2.96M |
| Net interest income | 0.14M | 0.94M | 1.27M | 2.85M | 2.96M |
| Extraordinary items | - | - | - | - | -0.07500M |
| Non recurring | - | - | - | - | -30.83500M |
| Other items | - | - | - | - | - |
| Income tax expense | 5.89M | -13.12500M | -18.76100M | 3.13M | -4.40300M |
| Total revenue | 847.13M | 747.59M | 560.41M | 547.40M | 444.94M |
| Total operating expenses | 529.12M | 482.88M | 377.12M | 324.46M | 262.55M |
| Cost of revenue | 311.93M | 272.21M | 222.24M | 175.44M | 152.41M |
| Total other income expense net | 22.13M | -3.00100M | 0.92M | 2.63M | -31.33900M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2.00200M | 2.62M | -19.25700M | 47.00M | 2.91M |
| Net income applicable to common shares | -2.00200M | 5.28M | -15.70200M | 48.46M | 6.60M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1370.89M | 1244.25M | 822.98M | 665.90M | 515.01M |
| Intangible assets | 81.16M | 90.62M | 10.64M | 25.41M | 27.25M |
| Earning assets | - | - | - | - | - |
| Other current assets | 30.28M | 29.16M | 18.73M | 14.85M | 12.20M |
| Total liab | 372.03M | 290.32M | 185.19M | 180.29M | 92.59M |
| Total stockholder equity | 998.86M | 953.93M | 641.50M | 485.89M | 422.24M |
| Deferred long term liab | 5.10M | 5.80M | - | - | 7.59M |
| Other current liab | 97.14M | 99.80M | 3.00M | 4.29M | 57.89M |
| Common stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.03M |
| Capital stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.03M |
| Retained earnings | 43.90M | 45.91M | 40.62M | 57.52M | 9.06M |
| Other liab | 3.28M | 3.56M | 8.01M | 15.25M | 26.53M |
| Good will | 166.05M | 166.39M | 8.37M | 7.66M | 7.81M |
| Other assets | 77.01M | 78.68M | 138.10M | 34.25M | 33.81M |
| Cash | 69.86M | 59.38M | 69.67M | 72.78M | 67.85M |
| Cash and equivalents | 69.86M | 59.38M | 69.67M | 72.78M | 67.85M |
| Total current liabilities | 144.93M | 123.20M | 105.93M | 91.05M | 66.06M |
| Current deferred revenue | 9.16M | - | 82.80M | 63.34M | - |
| Net debt | 165.91M | 114.17M | 7.61M | 9.52M | -67.85000M |
| Short term debt | 11.95M | 9.98M | 6.03M | 8.31M | 0.00000M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 235.77M | 173.55M | 77.28M | 82.30M | - |
| Other stockholder equity | 963.04M | 910.61M | 598.30M | 430.66M | 415.08M |
| Property plant equipment | 290.97M | 227.09M | 48.17M | 131.92M | 32.61M |
| Total current assets | 755.70M | 681.47M | 617.70M | 463.13M | 410.73M |
| Long term investments | - | - | - | - | 0.00000M |
| Net tangible assets | 751.65M | 696.92M | 622.49M | 449.30M | 384.39M |
| Short term investments | 118.17M | 195.50M | 195.16M | 116.61M | 133.04M |
| Net receivables | 203.38M | 133.94M | 114.61M | 105.90M | 81.90M |
| Long term debt | - | - | - | - | - |
| Inventory | 334.01M | 263.50M | 219.53M | 152.99M | 115.74M |
| Accounts payable | 26.68M | 13.42M | 14.11M | 15.11M | 8.18M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | -3.71000M | -0.27900M | 0.17M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -8.12400M | -2.63000M | 2.54M | -2.32400M | -1.94200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.04M | 0.04M | 0.04M | 0.04M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 43.90M | 45.91M | 40.62M | 57.52M | 9.06M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 12.79M | 12.98M | 8.71M | 2.95M | 0.88M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 615.19M | 562.78M | 205.28M | 202.77M | 104.28M |
| Capital lease obligations | 235.77M | 173.55M | 77.28M | 82.30M | - |
| Long term debt total | 24.86M | 26.52M | 27.07M | 26.75M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 74.09M | -3.07400M | -76.33300M | 18.03M | 29.63M |
| Change to liabilities | 23.93M | -1.56500M | 22.95M | -13.59500M | 15.56M |
| Total cashflows from investing activities | 54.79M | -21.73500M | -104.14900M | -12.71100M | -0.38500M |
| Net borrowings | -1.75100M | -1.45100M | -3.41800M | -2.57000M | -0.40400M |
| Total cash from financing activities | 11.62M | 0.84M | 134.92M | -8.95900M | -9.81500M |
| Change to operating activities | 9.57M | 7.75M | 14.39M | 3.56M | 16.46M |
| Net income | -2.00200M | 2.62M | -19.25700M | 47.00M | 2.91M |
| Change in cash | 10.48M | -10.29100M | -3.10900M | 4.93M | 17.21M |
| Begin period cash flow | 59.38M | 69.67M | 72.78M | 67.85M | 50.64M |
| End period cash flow | 69.86M | 59.38M | 69.67M | 72.78M | 67.85M |
| Total cash from operating activities | -55.66100M | 9.50M | -33.24200M | 26.65M | 28.81M |
| Issuance of capital stock | 0.00000M | 0.00000M | 134.76M | 0.00000M | 0.00000M |
| Depreciation | 24.32M | 16.41M | 12.89M | 8.10M | 6.17M |
| Other cashflows from investing activities | 74.09M | -0.40000M | -3.06000M | -8.63600M | -20.41400M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -74.63100M | -51.55400M | -56.98100M | -41.40700M | -22.28800M |
| Change to account receivables | -69.85700M | -21.34400M | -8.29500M | -25.02900M | -25.76200M |
| Sale purchase of stock | 21.55M | 18.37M | 151.30M | 13.90M | 12.79M |
| Other cashflows from financing activities | -0.39300M | -11.41800M | 3.58M | -15.37300M | -16.64200M |
| Change to netincome | 43.55M | 57.18M | 24.31M | -28.38600M | 19.32M |
| Capital expenditures | 19.30M | 21.18M | 24.76M | 22.11M | 9.60M |
| Change receivables | -69.85700M | -21.34400M | -8.29500M | 25.03M | -25.76200M |
| Cash flows other operating | -0.97400M | -9.32400M | -8.86500M | 4.00M | 33.07M |
| Exchange rate changes | - | - | - | - | -1.39500M |
| Cash and cash equivalents changes | 10.75M | -11.39700M | -2.47400M | -48.32200M | 17.21M |
| Change in working capital | -121.79800M | -70.41900M | -51.19000M | -56.84200M | -30.26000M |
| Stock based compensation | 37.38M | 65.76M | 25.54M | 21.48M | 18.42M |
| Other non cash items | 4.98M | 9.22M | 17.59M | 5.08M | 38.05M |
| Free cash flow | -74.95900M | -11.67800M | -57.99800M | 4.54M | 19.20M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PEN Penumbra Inc |
4.83 2.02% | 243.73 | 243.94 | 88.50 | 10.03 | 8.63 | 9.56 | 107.83 |
| ABT Abbott Laboratories |
1.29 1.15% | 113.22 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-0.41 0.11% | 358.76 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.41 0.51% | 80.44 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
1.08 1.23% | 89.11 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
One Penumbra Place, Alameda, CA, United States, 94502
| Name | Title | Year Born |
|---|---|---|
| Mr. Adam Elsesser | Co-Founder, Chairman, Pres & CEO | 1962 |
| Dr. Arani Bose M.D. | Co-Founder & Director | 1962 |
| Ms. Maggie S. Yuen | Chief Financial Officer | 1972 |
| Mr. Lambert Shiu | Chief Accounting Officer | 1980 |
| Ms. Johanna Roberts | Exec. VP, Gen. Counsel & Sec. | 1972 |
| Ms. Lynn Rothman | Exec. VP & Chief Bus. Officer | 1961 |
| Mr. Ben Sorci | Exec. VP of Operations | NA |
| Mr. Pankaj Tiwari | Exec. VP & Chief Information Officer | NA |
| Ms. Jee Hamlyn-Harris | Investor Relations Officer | NA |
| Ms. Shruthi Narayan | Director of Marketing - Vascular | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...